Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.

Blood
Norman J LacayoGary V Dahl

Abstract

Fms-like tyrosine kinase 3 (FLT3) mutations are associated with unfavorable outcomes in children with acute myeloid leukemia (AML). We used DNA microarrays to identify gene expression profiles related to FLT3 status and outcome in childhood AML. Among 81 diagnostic specimens, 36 had FLT3 mutations (FLT3-MUs), 24 with internal tandem duplications (ITDs) and 12 with activating loop mutations (ALMs). In addition, 8 of 19 specimens from patients with relapses had FLT3-MUs. Predictive analysis of microarrays (PAM) identified genes that differentiated FLT3-ITD from FLT3-ALM and FLT3 wild-type (FLT3-WT) cases. Among the 42 specimens with FLT3-MUs, PAM identified 128 genes that correlated with clinical outcome. Event-free survival (EFS) in FLT3-MU patients with a favorable signature was 45% versus 5% for those with an unfavorable signature (P = .018). Among FLT3-MU specimens, high expression of the RUNX3 gene and low expression of the ATRX gene were associated with inferior outcome. The ratio of RUNX3 to ATRX expression was used to classify FLT3-MU cases into 3 EFS groups: 70%, 37%, and 0% for low, intermediate, and high ratios, respectively (P < .0001). Thus, gene expression profiling identified AML patients with divergent prognoses w...Continue Reading

References

Jan 1, 1996·Acta Haematologica·O RosnetD Birnbaum
Dec 5, 1997·Breast Cancer Research and Treatment·K L CheungJ F Robertson
Mar 24, 1999·International Journal of Oncology·H ServeW E Berdel
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·C M PerouD Botstein
Oct 12, 2000·Biochemical and Biophysical Research Communications·S Zhang, H E Broxmeyer
Jan 11, 2000·Nucleic Acids Research·G SherlockJ M Cherry
Apr 6, 2001·Blood·J D Griffin
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·V G TusherG Chu
Jun 8, 2001·Bioinformatics·O TroyanskayaR B Altman
Jul 10, 2001·British Journal of Haematology·F M Abu-DuhierJ T Reilly
May 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·Robert TibshiraniGilbert Chu
Jun 12, 2002·Molecular Biology of the Cell·Michael L WhitfieldDavid Botstein
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louise M KellyD Gary Gilliland
Jun 28, 2002·Cancer Cell·Anders H Lund, Maarten van Lohuizen
Dec 6, 2002·Expert Review of Molecular Diagnostics·Jeffrey S Ross, Geoffrey S Ginsburg

❮ Previous
Next ❯

Citations

May 29, 2008·Current Treatment Options in Oncology·Jeffrey E Rubnitz
Jun 1, 2006·Current Hematologic Malignancy Reports·Kenneth I Mills, Amanda F Gilkes
Mar 30, 2011·Leukemia·K Theilgaard-MönchL Bullinger
Aug 30, 2008·Nature·Franz-Josef MüllerJeanne F Loring
May 3, 2005·Nature Reviews. Cancer·Karen BlythJames C Neil
Apr 4, 2006·Nature Reviews. Drug Discovery·Stephen F Kingsmore
Jan 18, 2012·The Pharmacogenomics Journal·D SanoudouD Pectasides
May 29, 2009·Briefings in Functional Genomics & Proteomics·Ulrike BacherTorsten Haferlach
Oct 4, 2005·The Cancer Journal·Charles G MullighanJames R Downing
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Meyling H CheokWilliam E Evans
Aug 18, 2006·Acta Haematologica·Elena SerranoJosep F Nomdedéu
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Mar 9, 2010·PloS One·Brady G Miller, John A Stamatoyannopoulos
Dec 18, 2004·Current Opinion in Hematology·Peter J M ValkBob Löwenberg
Oct 14, 2005·Expert Review of Anticancer Therapy·Edske ter Bals, Gertjan J L Kaspers
Oct 3, 2006·Expert Review of Molecular Diagnostics·Mar BellidoJerald P Radich
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Aug 25, 2009·Best Practice & Research. Clinical Haematology·Ulrike BacherTorsten Haferlach
Dec 10, 2015·Epigenomics·L Ashley WatsonNathalie G Bérubé
Jan 23, 2009·Leukemia Research·David P SteensmaEmily S Van Laar
Aug 12, 2008·Seminars in Oncology·Claudia D Baldus, Lars Bullinger
Feb 5, 2008·Pediatric Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Oct 18, 2015·Leukemia Research·Anar DamdinsurenHayato Miyachi
Apr 7, 2009·British Journal of Haematology·Ulrike BacherTorsten Haferlach
Oct 3, 2007·Genes, Chromosomes & Cancer·Derek L StirewaltJerald P Radich
Nov 26, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G Alex Bishop, Rohan B H Williams
Aug 31, 2006·British Journal of Haematology·Larissa BelovRichard I Christopherson
Dec 1, 2009·Heart Failure Clinics·Mark W GeraciRubin M Tuder
Apr 22, 2014·Experimental Hematology·Velizar Shivarov, Lars Bullinger
Jan 24, 2015·British Journal of Haematology·Marcos R H EstécioGuillermo Garcia-Manero
Jun 10, 2008·Cancer Cell·Junping WeiJames C Mulloy
Oct 9, 2014·Frontiers in Oncology·Colleen E Annesley, Patrick Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Alstrom Syndrome

Alstrom syndrome is a rare disorder characterized by early obesity, loss of central vision, diabetes mellitus, hearing loss, and short stature. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.